Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on Adlai Nortye (NASDAQ:ANL) with a Buy rating and annou...
Cantor Fitzgerald analyst Louise Chen reiterates Adlai Nortye (NASDAQ:ANL) with a Overweight.
Adlai Nortye a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced ...
